The FSP platform addresses limitations of other technologies by providing higher-density information with greater sensitivity, more flexibility and increased efficiency. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations, with direct sales force and support in North America, Europe, China, and Asia-Pacific regions.
Cyborg Score Rationale
2024 revenue was $200.45 million with 3.85% year-over-year growth, while losses improved significantly to -$6.02 million, 50.44% less than in 2023. Full-year 2025 revenue is expected to reach approximately $201 million with Q4 2025 growth of +8% year-over-year.
Top Insights
Named to TIME's 2026 America's Growth Leaders list; FSP platform cited in over 3,200 peer-reviewed publications.
Recent strength driven by Services, Reagents, Asia Pacific instruments, and return to positive instrument growth in EMEA.
Introduced Enhanced Small Particle Detection Option for Cytek Aurora CS system—first commercially available small particle detector on a cell sorter.
Growth in recurring services and reagents, plus expanding software and AI tools, enhances predictable revenue; broader adoption in healthcare research and global expansion positions Cytek for sustained growth.
Named Competitors
Flow Cytometry Solutions — Leading competitor in cell analysis and sorting